Stockreport

CG Oncology Undervalued Going Into A Busy 2026 [Seeking Alpha]

CG Oncology, Inc. - Common stock  (CGON) 
PDF Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ a [Read more]